Adamas Pharmaceuticals Inc (ADMS) was Upgraded by Mizuho to ” Buy” and the brokerage firm has set the Price Target at $22. Earlier the firm had a rating of “Neutral ” on the company shares. Mizuho advised their investors in a research report released on Jun 16, 2016.
Many Wall Street Analysts have commented on Adamas Pharmaceuticals Inc. Shares were Reiterated by Mizuho on May 12, 2016 to “Neutral” and Lowered the Price Target to $ 16 from a previous price target of $17 .Company shares were Reiterated by Mizuho on Apr 28, 2016 to “Neutral”, Firm has raised the Price Target to $ 17 from a previous price target of $14 .Adamas Pharmaceuticals Inc was Initiated by JMP Securities to “Mkt Outperform” on Apr 1, 2016.
Adamas Pharmaceuticals Inc opened for trading at $16.21 and hit $16.55 on the upside on Wednesday, eventually ending the session at $16.27, with a gain of 0.93% or 0.15 points. The heightened volatility saw the trading volume jump to 1,35,191 shares. Company has a market cap of $352 M.
In a different news, on Apr 20, 2016, Natalie Mcclure (SVP, Product Development) sold 36,000 shares at $18.50 per share price. According to the SEC, on Dec 9, 2015, Ivan M Lieberburg (director) sold 3,000 shares at $16.23 per share price. On Jun 17, 2015, Richard H Booth (director) sold 1,000 shares at $19.32 per share price, according to the Form-4 filing with the securities and exchange commission.
Adamas Pharmaceuticals Inc. is a specialty pharmaceutical company focused on development and commercialization of therapeutics targeting chronic disorders of central nervous systems (CNS). It is engaged in modifying pharmacokinetic (PK) profiles of approved drugs to create therapeutics for use alone and in fixed-dose combination products. It develops its lead product ADS-5102 (amantadine hydrochloride) for a complication associated with treatment of Parkinson’s disease known as levodopa induced dyskinesia and as a treatment for one or more additional CNS indications. Its other product candidate is ADS-8704. Through a partnership with Forest Laboratories Holdings Limited its portfolio includes two drugs commercially available in the United States: Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release capsules.